U.S. Markets open in 6 hrs 12 mins

Vitae Pharma's psoriasis drug succeeds in mid-stage study

March 16 (Reuters) - Drug developer Vitae Pharmaceuticals Inc said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial.

Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24 percent reduction, while patients who took the 700 mg dose showed a 30 percent reduction compared to a placebo.

Psoriasis, which affects about 7.5 million people in the United States, is a chronic autoimmune disorder affecting the skin, leading to red scaly patches that are often itchy and painful.

(Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak Dasgupta)